文献速递中医内科中药与中成药合理使用

中药治疗COVID-19:系统综述与Meta分析

Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis.
PubMed 文献 · J Integr Med · 2020-07-31

该系统综述与Meta分析检索6个数据库至2020年5月15日,纳入7项RCT共732例成人COVID-19患者。与单纯标准治疗相比,中药联合标准治疗在症状体征评分、CRP水平及肺部CT改善方面均更优,未记录显著不良事件。

要点

  • 中药联合标准治疗可改善COVID-19症状体征评分(SMD -1.30)。
  • 中药联合标准治疗可降低CRP水平(MD -11.82 mg/L)。
  • 中药联合标准治疗提高肺部CT改善率(RR 1.34),未记录显著不良事件。

核心结论

  • 当前证据表明,中药作为标准治疗的辅助治疗有助于改善COVID-19病例的治疗结局。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed/MEDLINE、Cochrane Library、ScienceDirect、Google Scholar、Wanfang Data和CNKI共6个数据库至2020年5月15日,纳入7项RCT共732例成人。
  • 纳入标准为同行评议期刊或未经同行评议的RCT,对照组接受标准治疗(SC),治疗组接受SC加中药。

主要发现

  • 与单纯SC相比,中药加SC在症状体征评分变化上更优(SMD -1.30,95%CI [-2.43, -0.16];3项研究;n=261;P=0.03)。
  • 与单纯SC相比,中药加SC在CRP水平(mg/L)上更优(MD -11.82,95%CI [-17.95, -5.69];5项研究;n=325;P=0.0002)。
  • 与单纯SC相比,中药加SC在肺部CT改善患者数上更优(RR 1.34,95%CI [1.19, 1.51];4项研究;n=489;P<0.00001)。
  • 纳入的RCT中未记录显著不良事件。

关键数值与推荐

  • 主要结局为治疗过程中症状和体征变化评分。
  • 次要结局包括炎症标志物水平、CT确认的肺炎改善及不良事件。
  • 二分类数据以风险比或风险比(95%CI)表示;连续数据以均数差(95%CI)表示,不同量表合并时用标准化均数差。

临床怎么用

  • 在标准治疗基础上加用中药可能有助于改善COVID-19患者的症状体征、CRP及肺部CT表现。
  • 需注意纳入研究数量有限,证据强度受样本量及方法学质量限制。

局限性

  • 纳入研究仅7项、共732例,样本量有限。
  • 检索截止至2020年5月15日,后续证据未纳入。
  • 纳入非同行评议文献,可能影响证据质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is currently no drug or therapy that cures COVID-19, a highly contagious and life-threatening disease. OBJECTIVE: This systematic review and meta-analysis summarized contemporary studies that report the use of Chinese herbal medicine (CHM) to treat COVID-19. SEARCH STRATEGY: Six electronic databases (PubMed/MEDLINE, Cochrane Library, ScienceDirect, Google Scholar, Wanfang Data and China National Knowledge Infrastructure) were searched from their beginning to May 15, 2020 with the following search terms: traditional Chinese medicine, Chinese medicine, Chinese herbal medicine, COVID-19, new coronavirus pneumonia, SARS-CoV-2, and randomized controlled trial. INCLUSION CRITERIA: Randomized controlled trials (RCTs) from peer-reviewed journals and non-reviewed publications were included. Further, included RCTs had a control group that was given standard care (SC; such as conventional Western medicine treatments or routine medical care), and a treatment group that was given SC plus CHM. DATA EXTRACTION AND ANALYSIS: Two evaluators screened and collected literature independently; information on participants, study design, interventions, follow-up and adverse events were extracted, and risk of bias was assessed. The primary outcomes included scores that represented changes in symptoms and signs over the course of treatment. Secondary outcomes included the level of inflammatory markers, improvement of pneumonia confirmed by computed tomography (CT), and adverse events. Dichotomous data were expressed as risk ratio or hazard ratio with 95% confidence interval (CI); where time-to-event analysis was used, outcomes were expressed as odds ratio with 95% CI. Continuous data were expressed as difference in means (MD) with 95% CI, and standardized mean difference (SMD) was used when different outcome scales were pooled. RESULTS: Seven original studies, comprising a total of 732 adults, were included in this meta-analysis. Compared to SC alone, CHM plus SC had a superior effect on the change of symptom and sign score (-1.30 by SMD, 95% CI [-2.43, -0.16]; 3 studies; n = 261, P = 0.03), on inflammatory marker C-reactive protein (CRP, mg/L; -11.82 by MD, 95% CI [-17.95, -5.69]; 5 studies; n = 325, P = 0.0002), on number of patients with improved lung CT scans (1.34 by risk ratio, 95% CI [1.19, 1.51]; 4 studies; n = 489, P < 0.00001). No significant adverse events were recorded in the included RCTs. CONCLUSION: Current evidence shows that CHM, as an adjunct treatment with standard care, helps to improve treatment outcomes in COVID-19 cases.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Fan AY, Gu S, Alemi SF, et al. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. J Integr Med. 2020. PMID: 32792254. doi:10.1016/j.joim.2020.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。